Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

11/10/2021 | 07:33am EST

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2021, VYNE Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2021. The press release is being furnished as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

Beginning on November 10, 2021, Company management will use the presentation attached as Exhibit 99.2 to this Current Report on Form 8-K in connection with investor meetings and industry conferences. In addition, slides 22 through 27 of the presentation will be discussed on today's earnings call.

The information in this Item 7.01 and Exhibit 99.2 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


The following exhibits are being furnished herewith.


Exhibit No.            Description

  99.1                   Press Release, dated November 10, 2021.

  99.2                   Corporate Presentation.

104                    Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses

All news about VYNE THERAPEUTICS INC.
01/14VYNE THERAPEUTICS : Unaudited Pro Forma Condensed Consolidated Financial Information - For..
PU
01/14VYNE THERAPEUTICS INC. Change in Directors or Principal Officers, Financial Statements..
AQ
01/14VYNE Therapeutics Inc. Announces Board Changes
CI
01/14Health Care Stocks Drop Premarket Friday
MT
01/13Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade
MT
01/13Wall Street Set for Narrow Gains; US Wholesale Prices Rise Less Than Expected in Decemb..
MT
01/13Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS In..
PR
01/13Journey Medical Acquires Vyne Therapeutics' Molecule Stabilizing Technology Franchise
MT
01/13VYNE THERAPEUTICS : Divests Topical Minocycline Assets - Form 8-K
PU
01/13VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Completion of Acquisi..
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 16,6 M - -
Net income 2021 -69,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,51x
Yield 2021 -
Capitalization 36,8 M 36,8 M -
Capi. / Sales 2021 2,22x
Capi. / Sales 2022 4,85x
Nbr of Employees 106
Free-Float 92,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,69 $
Average target price 5,80 $
Spread / Average Target 744%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-32.64%37
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.10%325 363
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%223 075